Lantheus Medical Imaging, Inc. develops, manufactures, and distributes diagnostic medical imaging products worldwide. The company offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. It offers DEFINITY, an injectable agent used during cardiac ultrasound or echocardiography for patients with suboptimal echocardiograms; TechneLite, a technetium generator used in nuclear medicine procedures; and Xenon Xe 133 Gas, a radiopharmaceutical gas that is used to assess pulmonary function. The company also provides Cardiolite, an injectable and technetium-labeled imaging agent...
331 Treble Cove Road
North Billerica, MA 01862
Founded in 1956
Lantheus Medical Imaging, Inc. Promotes Mary Anne Heino to the Position of Chief Operating Officer
Mar 16 15
On March 16, 2015, Lantheus Medical Imaging, Inc. announced its promotion of Mary Anne Heino to the position of Chief Operating Officer. Ms. Heino, age 55, had previously served as the company's Chief Commercial Officer, a position she held since joining the company in April 2013. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012.
Lantheus Medical Imaging, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Asset Write-Off Charges for the Fourth Quarter Ended December 31, 2014
Mar 4 15
Lantheus Medical Imaging, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenues were $76,969,000 against $71,668,000 last year. Operating income was $11,800,000 against operating loss of $1,334,000 last year. Income before income taxes was $1,869,000 against loss before income taxes of $11,555,000 last year. Net income was $300,000 against net loss of $12,302,000 last year. Net income, as adjusted was $1,510,000 against net loss, as adjusted of $6,120,000 last year. EBITDA was $17,496,000 against $4,710,000 last year. Adjusted EBITDA was $19,363,000 against $15,157,000 last year. Net cash used in operating activities was $3,875,000 against $3,856,000 last year. Capital expenditures were $2,834,000 against $1,299,000 last year.
For the year, revenues were $301,600,000 against $283,672,000 last year. Operating income was $41,809,000 against operating loss of $19,014,000 last year. Income before income taxes was $26,000 against loss before income taxes of $60,664,000 last year. Net loss was $1,169,000 against $61,678,000 last year. Net income, as adjusted was $41,000 against net loss, as adjusted of $48,708,000 last year. EBITDA was $60,557,000 against $6,789,000 last year. Adjusted EBITDA was $70,775,000 against $38,360,000 last year. Net cash provided by operating activities was $11,573,000 against net cash used in operating activities of $15,678,000 last year. Capital expenditures were $8,137,000 against $5,010,000 last year.
For the quarter, asset write-off was $107,000 against $18,091,000 last year.